Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1

Cancer Letters

Volumn 258, Issue 1, 2007, Pages 80-89

  Lu, Na ^a   Yang, Yong ^a   You, Qi Dong ^a   Ling, Yun ^a   Gao, Ying ^a   Gu, Hong Yan ^a   Zhao, Li ^a   Wang, Xiao Tang ^b   Guo, Qing Long ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

Author keywords

Angiogenesis; Gambogic acid; KDR Flk 1; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; GAMBOGIC ACID; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SYNAPTOPHYSIN; TYROSINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER TRANSPLANTATION; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RAT; TUMOR VASCULARIZATION; UMBILICAL VEIN; VASCULAR RING;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, LEWIS LUNG; CHICK EMBRYO; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LAMININ; LUNG NEOPLASMS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEOGLYCANS; TYROSINE; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XANTHONES;

GARCINIA; MUS; RATTUS;

EID: 35348952483     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.08.015     Document Type: Article

References (42)

1. Folkman J., and Hanahan D. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
2. Folkmann J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-6
3. Zetter B.R. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49 (1998) 407-424
4. Arasteh K., and Hannah A. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma. Oncologist Suppl. 5 49 (2000) 28-31
5. Carmeliet F.V., Breier P.G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (London) 380 (1996) 435-439
6. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
7. Kim K.J., Li B., Winer J., Armanini M., Gillett N., Phillips H.S., and Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
8. Auterhoff H., Frauendorf H., Liesenklas W., and Schwandt C. The chief constituents of gamboge resins. 1. Chemistry of gamboge. Arch. Pharm. 295/67 (1962) 833-846
9. Ollis W.D., Ramsay M.V.J., Sutherland I.O., and Mongkolsuk S. Constitution of gambogic acid. Tetrahedron 21 (1965) 1453-1470
10. Weakley T.J.R., Cai S.X., Zhang H.-Z., and Keana J.F.W. Crystal structure of the pyridine salt of gambogic acid. J. Chem. Crystallogr. 31 (2002) 501-505
11. Liu W., Guo Q.L., You Q.D., Zhao L., Gu H.Y., and Yuan S.T. Anticancer effect and apoptosis induction of gambogic acid in human gastric cancer line BGC-823. World J. Gastroenterol. 11 (2005) 3655-3659
12. Wu Z.Q., Guo Q.L., You Q.D., Zhao L., and Gu H.Y. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol. Pharm. Bull. 27 (2004) 1769-1774
13. Zhao L., Guo Q.L., You Q.D., Wu Z.Q., and Gu H.Y. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol. Pharm. Bull. 27 (2004) 998-1003
14. Yu J., Guo Q.L., You Q.D., Lin S.S., Li Z., Gu H.Y., Zhang H.W., Tan Z., and Wang X. Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells. Cancer Chemother. Pharmacol. 58 (2006) 434-443
15. Yu J., Guo Q.L., You Q.D., Zhao L., Gu H.Y., Yang Y., Zhang H.W., Tan Z., and Wang X. Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis 28 (2007) 632-638
16. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52 (1973) 2745-2756
17. Lee O.H., Kim Y.M., Lee Y.M., Moon E.J., Lee D.J., Kim J.H., Kim K.W., and Kwon Y.G. Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 264 (1999) 743-750
18. Ashton A.W., Yokota R., John G., Zhao S., Suadicani S.O., Spray D.C., and Ware J.A. Inhibition of endothelial cell migration, intercellular communication, and vascular tube formation by thromboxane A(2). J. Biol. Chem. 274 (1999) 35562-35570
19. Berger A.C., Wang X.Q., Zalatoris A., Cenna J., and Watson J.C. A murine model of ex vivo angiogenesis using aortic disks grown in fibrin clot. Microvasc. Res. 68 (2004) 179-187
20. Passaniti A. Extracellular matrix-cell interactions: Matrigel and complex cellular pattern formation. Lab Invest. 67 (1992) 804 (author reply 804-808)
21. Tan W.F., Lin L.P., Li M.H., Zhang Y.X., Tong Y.G., Xiao D., and Ding J. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur. J. Pharmacol. 459 (2003) 255-262
22. B.R.L. Xu, S.Y.X. Chen, Pharmacological Experimental Method, 1991, People's Medical Publishing House, Beijing, p. 1424.
23. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat. 36 (1995) 169-180
24. Hu Y., Yang Y., You Q.D., Liu W., Gu H.Y., Zhao L., Zhang K., Wang W., Wang X.T., and Guo Q.L. Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochem. Biophys. Res. Commun. 351 (2006) 521-527
25. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
26. Minchenko A., Bauer T., Salceda S., and Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Invest. 71 (1994) 374-379
27. Jun Y., Guo Q.L., You Q.D., Zhao L., Gu H.Y., Yang Y., Zhang H.W., Tan Z., and Wang X. Gambogic acid induced G2/M phase cell cycle arrest via disturbing CDK7 mediated phosphorylation of CDC2/P34 in human gastric carcinoma BGC-823 cells. Carcinogenesis (2006)
28. Pandey M.K., Sung B., Ahn K.S., Kunnumakkara A.B., Chaturvedi M.M., and Aggarwal B.B. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-[κ]B signaling pathway. Blood (2007)
29. Miller K.D., Sweeney C.J., and Sledge Jr. G.W. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 19 (2001) 1195-1206
30. Schirner M. Antiangiogenic chemotherapeutic agents. Cancer Metastasis Rev. 19 (2000) 67-73
31. Albertsson P., Lennernas B., and Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. Apmis 111 (2003) 995-1003
32. Clements M.K., Jones C.B., Cumming M., and Daoud S.S. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol. 44 (1999) 411-416
33. Grant D.S., Williams T.L., Zahaczewsky M., and Dicker A.P. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int. J. Cancer 104 (2003) 121-129
34. Yancopoulos G.D., Davis S., Gale N.W., Rudge J.S., Wiegand S.J., and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 407 (2000) 242-248
35. Ferrare N. VEGF and the quest for tumor angiogenesis factors. Nat. Rev. Cancer 2 (2002) 795-803
36. Klagsbrun M., and D'Amore P.A. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 7 (1996) 259-270
37. Bernatchez P.N., Soker S., and Sirois M.G. Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J. Biol. Chem. 274 (1999) 31047-31054
38. Davis-Smyth T., Chen H., Park J., Presta L.G., and Ferrara N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J. 15 (1996) 4919-4927
39. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., and Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269 (1994) 26988-26995
40. Heldin C.H. Dimerization of cell surface receptors in signal transduction. Cell 80 (1995) 213-223
41. Binetruy-Tournaire R., Demangel C., Malavaud B., Vassy R., Rouyre S., Kraemer M., Plouet J., Derbin C., Perret G., and Mazie J.C. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 19 (2000) 1525-1533
42. Papapetropoulos A., Garcia-Cardena G., Madri J.A., and Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100 (1997) 3131-3139